| 1 |
33291124 | Discovery of hCES2A inhibitors from Glycyrrhiza inflata via combination of docking-based virtual screening and fluorescence-based inhibition assays. | 2021 Jan 7 |
1 |
| 2 |
33568030 | Comparison of the Inhibitory Effects of Clotrimazole and Ketoconazole against Human Carboxylesterase 2. | 2021 |
3 |
| 3 |
33630990 | A highly selective near infrared fluorescent probe for carboxylesterase 2 and its biological applications. | 2021 Mar 17 |
6 |
| 4 |
34084136 | Discovery and Characterization of the Biflavones From Ginkgo biloba as Highly Specific and Potent Inhibitors Against Human Carboxylesterase 2. | 2021 |
1 |
| 5 |
34536357 | m6A modification impacts hepatic drug and lipid metabolism properties by regulating carboxylesterase 2. | 2021 Nov |
3 |
| 6 |
32961616 | Combined use of irinotecan and p53 activator enhances growth inhibition of mesothelioma cells. | 2020 Nov |
9 |
| 7 |
30551482 | Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy-induced gut toxicity in mice. | 2019 Jan |
2 |
| 8 |
29210644 | Carboxylesterase Inhibitors: An Update. | 2018 |
2 |
| 9 |
29261002 | Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. | 2018 Mar 4 |
3 |
| 10 |
29421708 | Characterization and structure-activity relationship studies of flavonoids as inhibitors against human carboxylesterase 2. | 2018 Apr |
2 |
| 11 |
29468758 | Evidence for Shikonin acting as an active inhibitor of human carboxylesterases 2: Implications for herb-drug combination. | 2018 Jul |
2 |
| 12 |
29651325 | The Relationship between TP53 Gene Status and Carboxylesterase 2 Expression in Human Colorectal Cancer. | 2018 |
4 |
| 13 |
29963254 | Two birds, one stone: hesperetin alleviates chemotherapy-induced diarrhea and potentiates tumor inhibition. | 2018 Jun 15 |
2 |
| 14 |
28126414 | Recent progress in the discovery of natural inhibitors against human carboxylesterases. | 2017 Mar |
1 |
| 15 |
26750665 | Gambogic acid potentiates clopidogrel-induced apoptosis and attenuates irinotecan-induced apoptosis through down-regulating human carboxylesterase 1 and -2. | 2016 Sep |
1 |
| 16 |
26900660 | Design, synthesis, and structure-activity relationship study of glycyrrhetinic acid derivatives as potent and selective inhibitors against human carboxylesterase 2. | 2016 Apr 13 |
4 |
| 17 |
26025324 | Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. | 2015 Aug |
9 |
| 18 |
26509550 | Effect of Cellular Location of Human Carboxylesterase 2 on CPT-11 Hydrolysis and Anticancer Activity. | 2015 |
7 |
| 19 |
24195516 | Relationship between the expression of CES2, UGT1A1, and GUSB in colorectal cancer tissues and aberrant methylation. | 2014 |
1 |
| 20 |
24439671 | Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells. | 2014 Feb |
1 |
| 21 |
24699684 | In vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2. | 2014 |
2 |
| 22 |
24727322 | P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. | 2014 Jun 15 |
1 |
| 23 |
24988246 | The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. | 2014 |
1 |
| 24 |
25260839 | Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11. | 2014 Sep |
1 |
| 25 |
23373735 | Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug. | 2013 Apr |
3 |
| 26 |
23480903 | Clinical implications of CES2 RNA expression in neuroblastoma. | 2013 Mar |
6 |
| 27 |
23648675 | Evaluation of the inhibitory effects of antihypertensive drugs on human carboxylesterase in vitro. | 2013 |
2 |
| 28 |
23756919 | Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study. | 2013 Aug |
2 |
| 29 |
21840303 | Hepatocyte growth factor suppresses the anticancer effect of irinotecan by decreasing the level of active metabolite in HepG2 cells. | 2011 Dec 1 |
5 |
| 30 |
20649590 | Biochemical and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin. | 2010 Aug |
1 |
| 31 |
19225040 | Different inhibitory effects in rat and human carboxylesterases. | 2009 May |
2 |
| 32 |
17483951 | Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. | 2008 Mar |
5 |
| 33 |
18771527 | Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma. | 2008 Nov |
5 |
| 34 |
17409690 | [Hydrolysis by carboxylesterase and disposition of prodrug with ester moiety]. | 2007 Apr |
1 |
| 35 |
17537833 | Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. | 2007 Sep |
2 |
| 36 |
17640957 | Haplotypes and a novel defective allele of CES2 found in a Japanese population. | 2007 Oct |
5 |
| 37 |
16271446 | Pharmacogenetics of irinotecan metabolism and transport: an update. | 2006 Mar |
2 |
| 38 |
16508919 | Expression of drug pathway proteins is independent of tumour type. | 2006 Jun |
1 |
| 39 |
15727486 | Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. | 2005 |
1 |
| 40 |
16203781 | Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. | 2005 Oct 1 |
4 |
| 41 |
15100172 | Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. | 2004 May |
9 |
| 42 |
15592324 | Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. | 2004 Dec |
9 |
| 43 |
12939466 | Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. | 2003 Aug |
3 |
| 44 |
14581373 | Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. | 2003 Oct 15 |
3 |
| 45 |
15618752 | Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2). | 2003 |
1 |
| 46 |
12171891 | Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. | 2002 Aug |
7 |
| 47 |
12171903 | Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. | 2002 Aug |
5 |
| 48 |
12237777 | Secreted and tumour targeted human carboxylesterase for activation of irinotecan. | 2002 Sep 9 |
2 |
| 49 |
12607608 | Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis. | 2002 Dec |
3 |
| 50 |
11177741 | Determinants of prognosis and response to therapy in colorectal cancer. | 2001 Mar |
1 |